Free Estriol ELISA kit

Name: Free Estriol ELISA kit
SKU: DEIA4569
Rating: 5 (1 reviews)

Regulatory status: For research use only, not for use in diagnostic procedures.

COA

SDS

Datasheet

Summary

Sample

serum

Intended Use

The Free Estriol ELISA Kit is an enzyme immunoassay for the quantitative measurement of free estriol (unconjugated estriol) in serum during the second half of pregnancy.

Contents of Kit

1. ##Microtiterwells##, 12 x 8 (break apart) strips, 96 wells
2. ##Standard## (Standard 0-5), 6 vials, 1 mL
3. ##Control Low & High##, 2 vials, 1 mL each
4. ##Enzyme Conjugate##, 1 vial, 14 mL
5. ##Substrate Solution##, 1 vial, 14 mL
6. ##Stop Solution##, 1 vial, 14 mL
7. ##Wash Solution##, 1 vial, 30 mL (40x concentrated).

Storage

2°C to 8°C

Performance Characteristics

##Assay Dynamic Range##
The range of the assay is between 0.075 - 40 ng/mL.

##Specificity of Antibodies (Cross Reactivity)##
The following substances were tested for cross reactivity of the assay:

n.d. = non detectable

##Sensitivity##
The analytical sensitivity of the ELISA was calculated by subtracting 2 standard deviations from the mean of 20 replicate analyses of the Standard 0 and was found to be 0.075 ng/mL.

##Reproducibility##
##Intra-Assay##
The within-assay variability is shown below:

##Inter-Assay##
The between-assay variability is shown below:

##Recovery##
Recovery of this ELISA was determined by adding increasing amounts of the analyte to three different patient sera containing different amounts of endogenous analyte. Each sample (non-spiked and spiked) was assayed and analyte concentrations of the samples were calculated from the standard curve. The percentage recoveries were determined by comparing expected and measured values of the samples.

##Linearity##

General Description

Estriol (E3) is the major estrogen formed by the fetoplacental unit during pregnancy. Unconjugated E3 passes through the placenta into the maternal circulation, where it is rapidly converted into glucuronide and sulfate derivatives to facilitate its excretion. The half-life of estriol in the maternal bloodstream is only 20-30 minutes. Its measurement, therefore offers a convenient and quick evaluation of current fetal status. Plasma estriol levels increase steadily throughout pregnancy and most rapidly during the third trimester (28-40 weeks). A sudden decrease in fetoplacental E3 production will result in a rapid fall in unconjugated E3 in the maternal serum. There are several potential advantages to measuring unconjugated E3 rather than total serum or urinary E3. Unconjugated estriol levels are free from effects related to maternal renal or hepatic disease, and are not altered by the administration of certain antibiotics. Unconjugated E3 more accurately reflects fetal outcome in diabetic pregnancies - and since no hydrolysis of unconjugated E3 is required, a more rapid tumaround for the test result is possible.

Standard Curve

##Standard## ##Optical Units (450 nm)##
Standard 0 (0.0 ng/mL) 1.79
Standard 1 (0.3 ng/mL) 1.48
Standard 2 (1.2 ng/mL) 1.18
Standard 3 (4.0 ng/mL) 0.81
Standard 4 (15.0 ng/mL) 0.52
Standard 5 (40.0 ng/mL) 0.38

Reconstitution And Storage

When stored at 2°C to 8°C unopened reagents will retain reactivity until expiration date. Do not use reagents beyond this date. Opened reagents must be stored at 2°C to 8°C. Microtiter wells must be stored at 2°C to 8°C. Once the foil bag has been opened, care should be taken to close it tightly again. Opened kits retain activity for two months if stored as described above.

Citations

Have you cited DEIA4569 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

A novel de novo frameshift mutation in NR0B1 and low prenatal estriol in adrenal hypoplasia congenita

ANNALS OF THE NEW YORK ACADEMY OF SCIENCES

Authors: Khattab, Ahmed; Nelson-Williams, Carol; Cabreza, Vivienne; Macdonald, Anne; Loring, Erin; Saland, Jeffrey; New, Maria I.

Abstract

Mutations in the gene NR0B1 have been associated with several clinical phenotypes of X-linked adrenal hypoplasia congenita (AHC). The degree and onset of adrenal insufficiency and involvement of hypogonadotropic hypogonadism is variable and may not be concordant with the identified mutation. We review a patient with AHC in which prenatal estriol levels were low, presenting with early-onset mineralocorticoid deficiency in the newborn period followed by glucocorticoid deficiency 2 years later. The reported child is hemizygous for a novel mutation that is deemed de novo in the ligand-binding site of the protein (DAX1) expressed by NR0B1. The identified frameshift mutation results in a T407N/fs protein change. Low prenatal estriol levels may represent a sensitive marker of potentially fatal disorders associated with adrenal insufficiency and should be utilized more frequently. Additionally, accurate reporting of mutations in NR0B1 and the associated phenotype are important to eventually establish a genotype-phenotype correlation that may help anticipate guidance in AHC.

Joint recommendations for the diagnosis and treatment of vulvo-vaginal atrophy in women in the peri- and post-menopausal phases from the Societa Italiana per la Menopausa (SIM) and the Societa Italiana della Terza Eta (SIGiTE)

MINERVA GINECOLOGICA

Authors: Cagnacci, Angelo; Gallo, Mario; Gambacciani, Marco; Lello, Stefano; Gambacciani, M.; Volpe, A.; Cagnacci, A.; Lanzone, A.; Di Carlo, C.; De Leo, V; Biglia, N.; Caruso, S.; Cicinelli, E.; Farris, M.; Gambera, A.; Guaschino, S.; Paoletti, A. M.; Russo, N.; Vicariotto, F.; Villa, P.; Gallo, M.; Nocera, F.; Maffei, S.; Pandolfo, M.; Lello, S.; Ambroggio, S.; Grassi, G.; De Seta, F.; Stoniati, M.; Gullo, D.; Becorpi, A.; Cancellieri, F.; Fiorillo, F.; Del Pup, L.; Mapell, C.; Ottanelli, S.

Abstract

Herein, joint recommendations for diagnosis and treatment of vulvo-vaginal atrophy (VVA) in women in the peri- and post-menopausal phases from the Societa Italians per la Menopausa (SIM) and the Societa Italiana della Terza Eta (SIGiTE) are presented. The recommendations are aimed at all healthcare personnel caring for women in the menopausal transition or postmenopausal phase, and are also intended to raise awareness of VVA. Recent data clearly indicate VVA is a highly prevalent condition among postmenopausal women, and that the vast majority of women with VVA are not adequately treated. In reality, diagnosis of VVA is simple and largely clinical. Many types of treatments are available for VVA, ranging from preventive education measures to local non-hormonal therapies, local agents that modulate hormonal receptors and systemic as well as laser therapy and radiofrequency. Regardless of the therapeutic approach adopted, greater communication between the physician and the woman with VVA should be actively encouraged. This is also in light of the difficulty of talking about the VVA and related disorders. Greater communication also encourages adequate therapy and thus minimizes the impact of VVA on the quality of life of the woman and her partner.